With AI, this pharmaceutical company aims at new marijuana drugs by amplifying its technological advantages!

[industry trends of pharmaceutical network] since 2018, industrial leprosy has become a hot topic in China Rhine biology, Yunnan Baiyao, Longjin pharmaceutical, Kangenbei, Zixin pharmaceutical, Yinhe biology, Huaren pharmaceutical, Kangenbei and other pharmaceutical enterprises have laid out this field one after another Recently, Xinbang pharmaceutical announced that its subsidiary, sinopeptide biochemical, has recently signed a memorandum of understanding on strategic cooperation with Nanjing suikun Intelligent Technology Co., Ltd in order to effectively accelerate the efficiency of new drug development and provide more patients with individualized treatment programs, the two sides plan to carry out strategic cooperation of artificial intelligence (AI) assisted new drug development According to the data, suikun intelligence is an AI + biotechnology company that uses artificial intelligence algorithm to explore disease targets, find new indications of known drugs, improve the efficiency of new drug screening, and improve the production of macromolecules Relying on Nanjing Turing Artificial Intelligence Research Institute, suikun intelligence has a number of international core technologies It has obvious advantages in a series of fields related to new drug research and development, such as target confirmation, new drug discovery, virtual high-throughput screening, multi-target drug development, and has a huge role in promoting new drug research and development The industry has pointed out that the current situation of industrial marijuana industry in the early stage of development in China can not be ignored, its development prospect and direction are also difficult to make accurate prediction at present, and the layout of enterprises are also facing uncertainty risks At present, the research and development of such drugs is still in the initial stage in the world, and only a few drugs have been approved However, it is clear that the value and market space of cannabis drug research and development in the future cannot be underestimated Xu Qi, vice general manager of Xinbang pharmaceutical and general manager of zhongpeptide biochemistry, said in an interview with the media that in the field of new drug development, the application of artificial intelligence in new drug research and development will provide many possibilities for Xinbang pharmaceutical to simplify and shorten its development time on the basis of its mastered traditional technical advantages and research and development capabilities According to the announcement, peptide biochemistry is mainly used in the research and development experience of small molecule related new drug design, drug property optimization, registration and application, and the development of new drug research based on natural compounds of cannabis plant, which is used to treat cancer, neuropathic pain, Alzheimer's disease and other major diseases Strategic cooperation with suikun intelligence will effectively accelerate the development efficiency of new drugs based on natural compounds of cannabis plants, meet the unmet clinical needs, and provide individualized treatment programs for more patients It is worth mentioning that in the medical industry, the extraction of cannabinoids from industrial marijuana has been proved to be able to treat epilepsy and other diseases With the continuous development of industrial marijuana, its value has also been continuously explored, and the detection equipment related to cannabinoids extraction has also ushered in development opportunities The detection object of cannabinoids mainly involves the detection of cannabinoid THC content, residual solvents, pesticides, heavy metals and microorganisms It is reported that Kangyong biology, a wholly-owned subsidiary of Xinbang pharmaceutical, has made strategic layout for cannabinoid drug testing equipment in the early days In 2018, the company sold more than 80 million yuan of THC detection and diagnostic reagent products, mainly to overseas markets such as the United States, Canada and Europe According to the intention of this cooperation, Xinbang pharmaceutical not only focuses on the field of cannabinoid detection, but also hopes to further deepen the research on new drugs of natural compounds of cannabis plants, improve the success rate of new drug discovery and reduce the cost of new drug research and development through cooperation and with the advantage of AI technology.